Marceau, Francois; Rivard, Georges E.; Gauthier, Julie M. et al.
Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene VariantsFRONTIERS IN MEDICINE. Bd. 7. 2020
Goldust, Mohamad; Heinz, Jaqueline; Gupta, Mrinal et al.
Merkel cell carcinoma-derived Erysipelas carcinomatosumDERMATOLOGIC THERAPY. 2020
Krumb, Matthias; Frey, Marie-Luise; Langhanki, Jens et al.
Multivalency Beats Complexity: A Study on the Cell Uptake of Carbohydrate Functionalized Nanocarriers to Dendritic CellsCELLS. Bd. 9. H. 9. 2020
Passlick, David; Reinholz, Jonas; Simon, Johanna et al.
Nanovaccine impact on dendritic cells: transcriptome analysis enables new insights into antigen and adjuvant effectsNANOMEDICINE. Bd. 15. H. 21. 2020 S. 2053-2069
Kaehler, Katharina C.; Hassel, Jessica C.; Heinzerling, Lucie et al.
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4-und PD-1-Antikorper beim metastasierten Melanom - ein UpdateJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 18. H. 6. 2020 S. 582-609
Goldust, Mohamad; Rokni, Ghasem Rahmatpour; Weinberg, Jeffrey M. et al.
Necrobiosis Lipoidica Mimicking Cutaneous Sarcoidosis Finally Treated With an Intralesional Injection of Corticosteroid: A Case ReportJOURNAL OF DRUGS IN DERMATOLOGY. Bd. 19. H. 1. 2020 S. 92-94
Hager, Simone; Fittler, Frederic Julien; Wagner, Ernst et al.
Nucleic Acid-Based Approaches for Tumor TherapyCELLS. Bd. 9. H. 9. 2020
Abdelmaksoud, Ayman; Goldust, Mohamad; Vestita, Michelangelo
Omalizumab and COVID-19 treatment: Could it help?DERMATOLOGIC THERAPY. Bd. 33. H. 4. 2020
Ascierto, Paolo Antonio; Del Vecchio, Michele; Mackiewicz, Andrzej et al.
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaJOURNAL FOR IMMUNOTHERAPY OF CANCER. Bd. 8. H. 1. 2020
Ascierto, P. A.; Del Vecchio, M.; Mackiewicz, A. et al.
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma (vol 8, e000391, 2020)JOURNAL FOR IMMUNOTHERAPY OF CANCER. Bd. 8. H. 2. 2020